Clinicians Push Earlier JAK Inhibitor Use in AD and Vitiligo
Fall Clinical Derm 2026 experts say JAK inhibitors should move earlier in AD and vitiligo care, before disease becomes chronic and pigment reserves are lost.
Topic
Vitiligo
Topic
Vitiligo
TRANQUILLO 2: Ritlecitinib Posts 21.86% F-VASI75 in Vitiligo
Ritlecitinib 100 mg drove a 21.86% F-VASI75 response at week 52 in the phase 3 TRANQUILLO 2 trial of nonsegmental vitiligo, again…
Upadacitinib Sustains Repigmentation at Week 76 in Non-Segmental Vitiligo
Long-term extension data show repigmentation maintained through 76 weeks in non-segmental vitiligo patients receiving oral upadac…
Selective Oral JAK/TEK Inhibitor Succeeds in Phase 3 Vitiligo Trial
A selective oral JAK/TEK inhibitor proved effective in a Phase 3 vitiligo trial, advancing targeted systemic therapy for a diseas…
Upadacitinib Sustains Vitiligo Repigmentation to 76 Weeks
Week-76 data from the phase 3 Viti-Up trials show upadacitinib drove continued facial and total-body repigmentation in nonsegment…
Gut–Skin Microbiome Pathways Move to the Center of Vitiligo Research
A Frontiers review traces vitiligo pathogenesis from gut and skin dysbiosis through metabolite-driven immune activation to melano…
Cureus Publishes Study on Dermoscopy in Hypopigmentation Disorders
A Cureus study pairs clinical assessment with dermoscopy in patients with hypopigmentation and depigmentation disorders, adding e…
Vitiligo Onset During Dupilumab Therapy in a Child with Atopic Dermatitis
A Frontiers case report and literature review document vitiligo emerging in a child on dupilumab for atopic dermatitis, adding a…